Testosterone for Women – Benefits vs. Risks

Many women in perimenopause or menopause describe fatigue, body composition shifts, and reduced sexual interest. The transcript frames testosterone as an option some clinics offer when conventional care feels cautious or incomplete. It emphasizes that evidence is still developing, so decisions should be individualized rather than routine. A major theme is that women’s hormone context is more complex than men’s, especially when estrogen and progestins enter the plan. The speaker notes that medical groups describe potential benefit, yet they also stress uncertainty and careful risk assessment. Because the uterus and prior gynecologic history change risk profiles, blanket protocols are discouraged throughout the talk. The framing stays focused on informed consent, close monitoring, and avoiding hidden use without clinician coordination.

When benefits are discussed, sexual function is presented as the most common reason women pursue testosterone therapy. Libido is described as both a mental drive and a physical response, with attention to clitoral sensitivity and potential enlargement. Beyond sex, some women report better mood, higher energy, and a stronger sense of confidence during day to day life. Body habit changes are mentioned, including improved training motivation and more noticeable muscle response to androgens. The transcript also flags that bone related benefits in women are uncertain, describing osteoporosis support as questionable. It repeatedly links benefit magnitude to dose and combinations, noting that more exposure tends to amplify noticeable effects. Overall, the benefits section is balanced with reminders that desired effects and adverse effects can overlap.

The risk discussion highlights delivery choices, including creams, gels, injections with micro dosing, and implanted pellets. Pellets are criticized for unpredictable rises and falls and for being a procedure that cannot be quickly adjusted. Strong contraindications are listed for women with histories of breast, ovarian, uterine, or cervical cancer. Virilizing effects are described as dose dependent, including voice changes, male pattern hair loss, unwanted hair growth, and acne. Cardiometabolic monitoring is emphasized using the ABCDS framework, including blood pressure and cholesterol vigilance. Calcium scoring is encouraged for postmenopausal women to better understand cardiovascular risk context. The closing message is to coordinate care with gynecology and internal medicine, and to avoid extreme add on practices like unnecessary anti estrogen drugs.